Apolizumab

DB06467InvestigationalProtein Based Therapies

Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

Mechanism: Apolizumab is a humanized monoclonal antibody directed against 1D10, a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells. Apolizumab induces complement-mediated cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis of 1D10 antigen-positive B cells in vitro.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.Curator reviewed
Also known as: IMMUNOGLOBULIN G1, ANTI-(HUMAN HISTOCOMPATIBILITY ANTIGEN HLA-DR) (HUMAN-MOUSE MONOCLONAL HU1D10.GAMMA.(SUB 1)-CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL HU1D10 LIGHT CHAIN, DIMER
Code names: HU-1D10

Resolves to

Compound

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Apolizumab, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.